William Schindler received his law degree from Stanford University and practiced law at Luce, Forward, Hamilton & Scripps in San Diego, California. He became an original investor in Sangart, the predecessor of Vivosang, in 1998.
Mr Schindler brokered the investment of Leucadia National Corporation (NYSE:LUK) in Sangart in 2002. That investment increased to over $250M by 2013, as Sangart grew to over 100 employees and conducted numerous clinical trials worldwide. During this time, Mr. Schindler remained involved in the company as a minority investor.
Mr. Schindler ultimately purchased all the intellectual property of Sangart. In the following years, he maintained the existing worldwide patents and prosecuted patent applications that were in the pipeline. In 2020 patents were granted for the next generation product, and in 2021 Vivosang Inc was founded to pursue development and commercialization of VS-101.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.